PHVS
Pharvaris N.V.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 2 ▲ Pharvaris presented positive Phase 3 RAPIDe-3 and long-term CHAPTER-…
- Mar 20 ▲ Pharvaris announced the publication of positive Phase 2 data from it…
- Jul 13 ▼ 1 insider sell $80.2K at $34.97
- Aug 14 ▼ Short interest jumps 48.7% to 1.78M
- Aug 14 ▼ 1 insider sell $79.7K at $34.77
- Sep 8 to Sep 23 ▼ 10 days of insider sells: $20.3M by 10 insiders, avg $36.49
- Sep 8 ▲ Pharvaris announced overwhelmingly positive topline data from the CH…
- Sep 8 FDA: Pharvaris Announces Positive Topline Data from CHAPTER-3 P…
- Sep 24 ▼ Eight Pharvaris insiders sold a total of $7.35M in open-market sales…
- Sep 25 ▼ A significant insider selling cluster at Pharvaris N.V. (PHVS) total…
- Oct 23 ▲ B of A Securities upgrades
- Nov 12 ▲ Pharvaris presented positive Phase 3 CHAPTER-3 data at ACAAI 2026, s…
Signal stack
Where each data set points today.
- InsidersBEARISH
10 insiders sold $20.5M.
- InstitutionsBULLISH
Q3 2026: 27 added (1 new), 4 trimmed or exited.
- AnalystsBULLISH
20 of 21 rate it Buy or better.
- EstimatesRISING
Current-quarter EPS estimate −$0.773 → −$0.703 over 90 days. 3 up, 8 down in 30 days.
- Short sellersSTEADY
Short interest +3.0% to 2.54M shares. 3.6 days to cover, ≈3.6% of shares.
- TrendRANGE
2% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | ADD | $30.7M |
| MORGAN STANLEY | DOUBLED | $13.1M |
| BNP Paribas Asset Management Holding S.A. | DOUBLED | $13.0M |
| JANE STREET GROUP, LLC | DOUBLED | $12.0M |
| UBS Group AG | ADD | $11.1M |
| Qube Research & Technologies Ltd | DOUBLED | $9.0M |
| TD ASSET MANAGEMENT INC | ADD | $2.3M |
| Swiss National Bank | ADD | $1.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
21 analysts| Date | Firm | Rating |
|---|---|---|
| Oct 23, 2026 | B of A Securities UPGRADE | Buy |
| Sep 10, 2026 | Guggenheim MAINTAIN | Buy |
| Sep 9, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Sep 9, 2026 | Leerink Partners MAINTAIN | Outperform |
| Sep 9, 2026 | Wells Fargo MAINTAIN | Overweight |
| Sep 9, 2026 | RBC Capital MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Lu Peng President Nov 12, 2026 | TAX W/H | $4.0K |
Lu Peng President Nov 11, 2026 | TAX W/H | $3.7K |
Lu Peng President Oct 12, 2026 | TAX W/H | $3.6K |
Lu Peng President Oct 11, 2026 | TAX W/H | $3.4K |
Monges Viviane Director Sep 23, 2026 | EXERCISE | $96.4K |
Monges Viviane Director Sep 23, 2026 | SELL | $395.5K |
Lu Peng President Sep 22, 2026 | EXERCISE | $117.3K |
Schikan Johannes Gerardus Christiaan Petrus Director Sep 22, 2026 | EXERCISE | $16.0K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.70 | -$0.76–-$0.65 | +8.8% | $0.00 |
| Next Q | -$0.79 | -$0.96–-$0.66 | +1.2% | $0.00 |
| Current FY | -$2.64 | -$2.79–-$2.46 | +4.7% | $0.00 |
| Next FY | -$2.69 | -$3.45–-$2.19 | +1.1% | $33.2M |
Short side
FINRA· Oct 30, 2026SecBot reports
41 filings · 10 press releases · 1 bullish · 13 bearish · 1 mixed · 26 neutral- NEUTRAL SC 13GNov 16, 2026
Wellington Management Group LLP disclosed a 9.5% passive stake in Pharvaris N.V. via a new Schedule 13G, reporting 6,696,804 common shares as of September 30, 2026. This is a new position from a major asset manager, contrasting with General Atlantic's recent exit below 5%.
🔒 Fresh report (last 24h), subscribers only
- BEARISH SC 13G/ANov 13, 2026
General Atlantic filed Amendment No. 4 to its Schedule 13G for Pharvaris N.V., reporting a 0.6%…
General Atlantic's exit filing signals a complete unwinding of a once-significant position. Monitor for any additional insider selling or further institutional exits that could pressure the stock.
- BULLISH PRESS RELEASENov 12, 2026
Pharvaris presented positive Phase 3 CHAPTER-3 data at ACAAI 2026, showing deucrictibant XR…
Watch for NDA/MAA submissions for deucrictibant XR prophylaxis; the company already has an NDA/MAA under review for the on-demand IR formulation. Regulatory decisions and potential commercial launch…
- NEUTRAL 6-KNov 12, 2026
Pharvaris reported Q3 2026 results showing a net loss of EUR 47.4M ($0.67 per share), wider than…
The PDUFA date of April 23, 2027 for deucrictibant IR is the primary near-term catalyst. Monitor for any FDA advisory committee meeting announcements and the CREAATE topline data expected in Q1…
All PHVS filing & press-release reports (51)
- SC 13G reportNov 16, 2026
- SC 13G/A reportNov 13, 2026
- PRESS-RELEASE reportNov 12, 2026
- 6-K reportNov 12, 2026
- PRESS-RELEASE reportNov 12, 2026
- CLUSTER reportSep 25, 2026
- CLUSTER reportSep 24, 2026
- CLUSTER reportSep 24, 2026
- CLUSTER reportSep 23, 2026
- CLUSTER reportSep 21, 2026
- 144 reportSep 17, 2026
- CLUSTER reportSep 17, 2026
- CLUSTER reportSep 17, 2026
- CLUSTER reportSep 16, 2026
- CLUSTER reportSep 15, 2026
- 144 reportSep 14, 2026
- CLUSTER reportSep 14, 2026
- CLUSTER reportSep 11, 2026
- 6-K reportSep 8, 2026
- 6-K reportAug 12, 2026
- PRESS-RELEASE reportAug 12, 2026
- PRESS-RELEASE reportAug 6, 2026
- PRESS-RELEASE reportJul 6, 2026
- CLUSTER reportJul 1, 2026
- CLUSTER reportJun 29, 2026
- 144 reportJun 25, 2026
- 144 reportJun 15, 2026
- PRESS-RELEASE reportJun 15, 2026
- PRESS-RELEASE reportMay 29, 2026
- CLUSTER reportMay 26, 2026
- CLUSTER reportMay 26, 2026
- CLUSTER reportMay 22, 2026
- 144 reportMay 21, 2026
- CLUSTER reportMay 20, 2026
- 144 reportMay 20, 2026
- CLUSTER reportMay 19, 2026
- PRESS-RELEASE reportMay 12, 2026
- 6-K reportMay 11, 2026
- PRESS-RELEASE reportMay 11, 2026
- 424B5 reportMay 8, 2026
- PRESS-RELEASE reportMay 8, 2026
- CLUSTER reportApr 30, 2026
- CLUSTER reportApr 23, 2026
- CLUSTER reportApr 16, 2026
- CLUSTER reportApr 16, 2026
- 144 reportApr 8, 2026
- 6-K reportApr 2, 2026
- PRESS-RELEASE reportApr 2, 2026
- PRESS-RELEASE reportMar 20, 2026
- PRESS-RELEASE reportMar 11, 2026
- PRESS-RELEASE reportMar 2, 2026